Wuhan Xirui Pharmaceutical Technology Co. Ltd. has synthesized new amphotericin B amide derivatives that are potentially useful for the treatment of fungal infection.
Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.
At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.
Helmholtz Zentrum München Universität Hannover has disclosed new heterocyclic compounds designed for use in the treatment of cancer and viral infection.
Researchers from the Indian Institute of Technology Bombay have reported the preclinical development of a new synthetic antimicrobial class incorporating organic metallophores, which yielded two optimized leads – VY-AD-4-11-6 and VY-AD-4-22-6 – from a 30-compound SAR series.
Researchers from GSK plc and collaborators described the identification of MMV-1581361, a PfATP4 inhibitor, and its efficacy in models of malaria. The compound originates from MMV-020136, following structure-activity relationship studies to optimize antimalarial activity.
CAR T-cell therapy can be applied to treat some chronic infectious diseases, particularly to provide a functional cure for HIV-1 in people living with HIV. However, the effectiveness of CAR T cells for persistent suppression of HIV still faces many constraints, including the high mutation rate of reverse transcriptase, which enables the emergence of immune escape viral variants.
Researchers from Chengdu Kanghua Biological Products Co. Ltd. recently published information on their novel varicella zoster virus (VZV) mRNA vaccine candidate (KH014). KH014 contains sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in ionizable lipid nanoparticles.
A team at the Virginia Polytechnic Institute and State University applied a drug repurposing strategy and screened a library of 2,528 small molecules targeting G protein-coupled receptors (GPCRs) and related signaling pathways for the ability to inhibit the growth of Neisseria gonorrhoeae.
Tessera Therapeutics Inc. has received a grant from the Gates Foundation to support early-stage research exploring multiple genetic approaches aimed at developing a scalable cure for HIV. This research will evaluate several potential strategies leveraging Tessera’s Gene Writing platform to engineer immune cells in vivo.
RSS
